School of Medicine


Showing 1-10 of 44 Results

  • Christine Anastasiou, MD, MAS

    Christine Anastasiou, MD, MAS

    Clinical Assistant Professor, Medicine - Immunology & Rheumatology

    BioDr. Anastasiou is a board-certified, fellowship-trained rheumatologist with the Stanford Health Care Immunology and Rheumatology Clinic. She is also a clinical assistant professor in the Department of Medicine, Division of Immunology and Rheumatology at Stanford University School of Medicine.

    Dr. Anastasiou specializes in diagnosing and treating patients with rheumatic diseases. She has a special interest in ankylosing spondylitis, systemic lupus erythematosus, rheumatoid arthritis, and idiopathic inflammatory myopathies.

    Her scholarly work includes epidemiologic studies and clinical trials focused on improving safety and health outcomes for people with chronic rheumatic diseases. Dr. Anastasiou has served as an investigator and collaborator for clinical trials of new therapies to treat rheumatic disease. She is actively involved in medical education through developing and leading patient, medical student, resident, and fellow educational programs.

    Dr. Anastasiou is a member of the American College of Rheumatology (ACR). She has published her research in peer-reviewed journals, including Arthritis Care & Research and Lupus Science & Medicine. She has delivered lectures and presentations across the country and abroad on various topics related to rheumatology.

  • Matthew C. Baker, MD MS

    Matthew C. Baker, MD MS

    Assistant Professor of Medicine (Immunology and Rheumatology)
    On Partial Leave from 02/17/2025 To 05/18/2025

    BioDr. Baker is the Associate Division Chief in the Division of Immunology and Rheumatology at Stanford University and the Co-Founder and Co-Director of the Stanford Multidisciplinary Sarcoidosis Program. He received his bachelor's degree from Pomona College, his medical degree from Harvard Medical School, and his master's degree in Epidemiology and Clinical Research from Stanford University. He completed his Internal Medicine residency at the Massachusetts General Hospital and his Rheumatology fellowship at Stanford University. Dr. Baker has established a clinical research program that is focused on clinical trials, epidemiological studies, and bench-to-bedside translational research. He has designed and led investigator-initiated and industry sponsored clinical trials with a focus on sarcoidosis, IgG4-related disease, Sjogren's syndrome, and rheumatoid arthritis. He also utilizes large databases to study osteoarthritis, with an interest in repurposing existing drugs for the treatment of osteoarthritis.

  • Yashaar Chaichian, MD

    Yashaar Chaichian, MD

    Clinical Associate Professor, Medicine - Immunology & Rheumatology

    Current Research and Scholarly InterestsSystemic lupus erythematosus
    CTD-associated interstitial lung disease

  • Alvina Dor-Yan Chu

    Alvina Dor-Yan Chu

    Adjunct Clinical Assistant Professor, Medicine - Immunology & Rheumatology

    BioAlvina Chu, MD, is an adjunct clinical faculty member within the Division of Immunology and Rheumatology. She has practiced rheumatology for more than 10 years, specializing in treatment of a wide range of chronic inflammatory conditions including rheumatoid arthritis, lupus, vasculitis, and gout.

    She holds a longstanding scientific interest in immunology, especially the role of B-cell signaling mechanisms in lupus and other autoimmune diseases.

    In addition to taking care of patients in clinic and in the hospital, Dr. Chu enjoys teaching and mentoring fellows, residents, and medical students.

  • Lorinda Chung

    Lorinda Chung

    Professor of Medicine (Immunology and Rheumatology) and, by courtesy, of Dermatology

    Current Research and Scholarly InterestsMy research interests focus on all aspects of systemic sclerosis. I am currently involved in clinical, translational, and epidemiologic research in these areas, and dedicate a substantial portion of my research time to investigator-initiated and multi-center clinical trials of novel therapeutics for the treatment of systemic sclerosis.

  • Edgar Engleman

    Edgar Engleman

    Professor of Pathology and of Medicine (Immunology and Rheumatology)

    Current Research and Scholarly InterestsDendritic cells, macrophages, NK cells and T cells; functional proteins and genes; immunotherapeutic approaches to cancer, autoimmune disease, neurodegenerative disease and metabolic disease.

  • Robert Michael Fairchild

    Robert Michael Fairchild

    Assistant Professor of Medicine (Immunology and Rheumatology)

    Current Research and Scholarly InterestsDr. Fairchild’s research interests center on novel applications of ultrasonography in rheumatologic disease. Current active research endeavors include using ultrasound 1) to evaluate articular and soft tissue manifestations of systemic sclerosis, 2) to screen, detect and monitor of connective tissue disease associated interstitial lung disease, 3) and applying deep learning techniques to rheumatology ultrasound and imaging.

  • Titilola Falasinnu

    Titilola Falasinnu

    Assistant Professor of Medicine (Immunology and Rheumatology) and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (Adult Pain)

    BioI am primarily a lupus researcher and identify as a pain scientist and methodologist in this field. Systemic lupus erythematosus (SLE) disproportionately affects women and racial minorities and is the fifth most common cause of death among 15- to 24-year-old Black and Hispanic women in the U.S., highlighting its significant public health impact. More than half of patients with SLE experience chronic pain, often secondary to SLE itself or overlapping conditions (e.g., migraines, low back pain, fibromyalgia), contributing significantly to disability and impaired quality of life. Chronic pain is not merely a symptom but a disease in its own right—one that deserves the same rigorous study and clinical attention as comorbidities like kidney disease and cardiovascular disease in rheumatology. The enormous global burden of chronic pain underscores the urgent need for a clear, standardized definition of pain as a disease, particularly in autoimmune rheumatic diseases where pain can arise from inflammatory, nociplastic, and biopsychosocial mechanisms. Without recognizing pain as a distinct disease entity, its mechanisms remain poorly understood, and effective treatment strategies remain underdeveloped.

    I am a co-Principal Investigator of the Pain Intelligence Lab, where our mission is to advance the study of pain as a disease in rheumatology through two primary objectives. First, we develop and validate computational methods that enable clinicians and researchers to leverage electronic health records, administrative claims, and disease registries to study chronic pain as a distinct disease entity in rheumatology. By applying machine learning, natural language processing, and real-world data analysis, we seek to enhance pain phenotyping, classify distinct pain subtypes, and develop predictive models for treatment response. Second, we use a biopsychosocial framework to examine the predictive power of biomarkers and psychosocial measures in rheumatologic pain. By integrating biological, psychological, and social determinants of pain, we aim to conduct rigorous, patient-oriented research that translates targeted assessments into mechanistically informed, personalized treatment approaches for optimized clinical care. Ultimately, my long term career goal is to bridge the gap between research and clinical practice, ensuring that pain management in autoimmune rheumatic diseases is precise, equitable, and optimized for improved patient outcomes.

  • C. Garrison Fathman

    C. Garrison Fathman

    Professor of Medicine (Immunology and Rheumatology), Emeritus

    Current Research and Scholarly InterestsMy lab of molecular and cellular immunology is interested in research in the general field of T cell activation and autoimmunity. We have identified and characterized a gene (GRAIL) that seems to control regulatory T cell (Treg) responsiveness by inhibiting the Treg IL-2 receptor desensitization. We have characterized a gene (Deaf1) that plays a major role in peripheral tolerance in T1D. Using PBC gene expression, we have provisionally identified a signature of risk and progression in T1D.

  • Mark Genovese

    Mark Genovese

    James W. Raitt M.D. Professor, Emeritus

    Current Research and Scholarly InterestsClinical trials and interventions in the rheumatic diseases including Rheumatoid Arthritis,Systemic Lupus Erythematosus, Systemic Sclerosis, Osteoarthritis.